<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-green ">
                        72.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=72.0 class=" progress-green ">72.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-orange ">
                        55.56%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=55.55555555555556 class=" progress-orange ">55.56%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">72%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Based on the provided scores, the most important action to improve your RAG system is to focus on enhancing the performance on complex questions, as they have the lowest score. Additionally, consider reviewing the coverage and quality of your knowledge base across all topics to ensure consistent performance.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"376fa9c0-6897-46b5-8bd7-f5c900294d34":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1431","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1433","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1440","attributes":{"factors":["Antihypertensive Medications","Lisinopril and Hydrochlorothiazide","Tapentadol Medication","Tizanidine Hydrochloride"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1441"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1442"},"title":{"type":"object","name":"Title","id":"p1438","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1460","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1428","attributes":{"selected":{"type":"object","name":"Selection","id":"p1429","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1430"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"chzHcRzHS0CqqqqqqqpQQAAAAAAAAFlA27Zt27ZtVUA="},"shape":[4],"dtype":"float64","order":"little"}],["metadata_values",["Antihypertensive Medications","Lisinopril and Hydrochlorothiazide","Tapentadol Medication","Tizanidine Hydrochloride"]],["colors",["#a50026","#f88b51","#006837","#b1dd71"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1461","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1462"}}},"glyph":{"type":"object","name":"HBar","id":"p1457","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1458","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1459","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1469","attributes":{"data_source":{"id":"p1428"},"view":{"type":"object","name":"CDSView","id":"p1470","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1471"}}},"glyph":{"type":"object","name":"HBar","id":"p1466","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1467","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1468","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1479","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1473","attributes":{"selected":{"type":"object","name":"Selection","id":"p1474","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1475"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1480","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1481"}}},"glyph":{"type":"object","name":"Line","id":"p1476","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1477","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1478","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1439","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1453","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1448","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1449"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1450"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1451"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1443","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1444","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1445"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1446"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1447","attributes":{"axis":{"id":"p1443"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1452","attributes":{"dimension":1,"axis":{"id":"p1448"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1472","attributes":{"location":72.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1482","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1483","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1479"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"376fa9c0-6897-46b5-8bd7-f5c900294d34","roots":{"p1431":"c0db2285-1725-4695-a73e-e9859d54f4cc"},"root_ids":["p1431"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="c0db2285-1725-4695-a73e-e9859d54f4cc" data-root-id="p1431" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"0ae75cde-86b6-472e-900c-46586da3b0a8":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1362","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1292","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1246","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1255","attributes":{"start":-11.49420461654663,"end":-3.3945081710815432}},"y_range":{"type":"object","name":"Range1d","id":"p1256","attributes":{"start":-2.7184320986270905,"end":10.954908847808838}},"x_scale":{"type":"object","name":"LinearScale","id":"p1257"},"y_scale":{"type":"object","name":"LinearScale","id":"p1258"},"title":{"type":"object","name":"Title","id":"p1253","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1286","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1243","attributes":{"selected":{"type":"object","name":"Selection","id":"p1244","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1245"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["topic",["Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Tizanidine Pharmacology","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs","Prescription Drugs"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],["content",["ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\nphenylephrine hydrochloride tablet, coated \\n \\nMARC GLASSMAN, INC.\\n----------\\n1128B-MAR-2022-1005\\nDrug Facts\\nActive ingredients \\n(in each caplet)\\nPurpose\\nAcetaminophen 325 mg\\nPain reliever\\nChlorpheniramine maleate\\n2 mg\\nAntihistamine\\nPhenylephrine HCl 5 mg\\nNasal decongestant\\nUses\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\nallergies:\\nheadache\\nsinus congestion and pressure\\nnasal congestion\\nrunny nose...","If a skin reaction occurs, stop use and seek medical help right away.\\nDo not use\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\npharmacist.\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\ndr...","800-222-1222). Quick medical attention is critical for adults as well as for children even if\\nyou do not notice any signs or symptoms.\\nDirections\\ndo not take more than directed (see \\noverdose warning\\n)\\nadults and\\nchildren 12\\nyears and over\\ntake 2 caplets every 4 hours\\nswallow whole; do not crush,\\nchew, or dissolve\\ndo not take more than 10 caplets\\nin 24 hours\\nchildren under \\n12 years\\nask a doctor\\nOther information\\nstore between 20\\u00b0-25\\u00b0C (68\\u00b0-77\\u00b0F) in a dry place\\nretain carton for complete product...","ALLERGY MULTI SYMPTOM  \\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:68998-228\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCHLORPHENIRAMINE MALEATE\\n (UNII: V1Q0O9OJ9Z) \\n(CHLORPHENIRAMINE -\\nUNII:3U6IO1965U)\\nCHLORPHENIRAMINE\\nMALEATE\\n2 mg\\nPHENYLEPHRINE HYDROCHLORIDE\\n (UNII: 04JA59TNSJ) \\n(PHENYLEPHRINE -\\nUNII:1WS297W6MV)\\nPHENYLE...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","ATHLETES FOOT- butenafine hydrochloride cream \\n \\nRite Aid Corporation\\n----------\\nAthlete&#x27;s Foot Cream\\nDrug Facts\\nActive ingredient\\nButenafine hydrochloride 1%\\nPurpose\\nAntifungal\\nUses\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\nfoot is unknown.\\ncures most jock itch and ringworm\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\nWarnings\\nFor external use only\\nDo not use\\non nails or scalp\\nin or near the mouth or the eyes\\nfor vag...","1 week twice a day or 4 weeks once a day\\nfor jock itch and ringworm:\\napply once a day to affected skin for 2 weeks or as\\ndirected by a doctor.\\nwash hands after each use\\nchildren under 12 years: ask a doctor\\nOther information\\ndo not use if seal on tube is broken or not visible\\nstore between 20\\u00ba to 25\\u00ba C (68\\u00ba to 77\\u00ba F)\\nInactive ingredients\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...","RITE \\nAID \\n \\nPHARMACY\\nclinically proven to cure \\nmost athlete&#x27;s foot between the toes\\nfoot care \\nbutenafine\\nhydrochloride cream 1%\\nantifungal\\nNET WT 0.42 OZ (12 g)\\n\\u00ae","ATHLETES FOOT  \\nbutenafine hydrochloride cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11822-2100\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nBUTENAFINE HYDROCHLORIDE\\n (UNII: R8XA2029ZI) \\n(BUTENAFINE -\\nUNII:91Y494NL0X)\\nBUTENAFINE\\nHYDROCHLORIDE\\n10 mg\\n in 1 g\\nInactive Ingredients\\nIngredient Name\\nStrength\\nBENZYL ALCOHOL\\n (UNII: LKG8494WBH)\\n \\nCETYL ALCOHOL\\n (UNII: 936JST6JCN)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n...","Rite Aid Corporation\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nANDA\\nANDA205181\\n11/17/2017\\nLabeler - \\nRite Aid Corporation \\n(014578892)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nTaro Pharmaceuticals Inc.\\n206263295\\nmanufacture(11822-2100)\\n \\nRevised: 7/2024","ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\nmethoxycinnamate cream \\n \\nC&amp;BCOSMETIC Co.,Ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nDrug Facts\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\nWater, Glycerin, Butylene Glycol, Etc\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\nk...","ABALONE CRYSTALDOUBLE EX CC  \\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:60611-0008\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength","C&amp;BCOSMETIC Co.,Ltd.\\nNIACINAMIDE\\n (UNII: 25X51I8RD4) \\n(NIACINAMIDE - UNII:25X51I8RD4)\\nNIACINAMIDE\\n2 g  in 100 mL\\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP) \\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\nTITANIUM DIOXIDE\\n4.694 g  in 100 mL\\nADENOSINE\\n (UNII: K72T3FS567) \\n(ADENOSINE - UNII:K72T3FS567)\\nADENOSINE\\n0.04 g  in 100 mL\\nOCTINOXATE\\n (UNII: 4Y5P7MUD51) \\n(OCTINOXATE - UNII:4Y5P7MUD51)\\nOCTINOXATE\\n7 g  in 100 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C...","ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","K2resource co., ltd.\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:72191-0100\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSODIUM BICARBONATE\\n (UNII: 8MDF5V39QO) \\n(SODIUM CATION -\\nUNII:LYR4M0NH37)\\nSODIUM\\nBICARBONATE\\n36.2 g  in 100 mg\\nXYLITOL\\n (UNII: VCQ006KQ1E) \\n(XYLITOL - UNII:VCQ006KQ1E)\\nXYLITOL\\n5 g  in 100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMENTHOL\\n (UNII: L7T10EIP3A)\\n \\nProduct Characteristics\\nCo...","CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\n \\nCertus Medical, Inc.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\nDrug Facts Box OTC Active Ingredient Section\\nPovidone Iodine USP 10%\\nequivalent to 1% titratable iodine\\nDrug Facts Box OTC Purpose Section\\nAntiseptic\\nDrug...","Drug Facts Box OTC General Precautions Section\\nstore at room temperature 15\\n - 30\\n C (59\\n - 86\\n F)\\nDrug Facts Box OTC Inactive Ingredient Section\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\nCertus PVP-1 Prep Swabstick \\n210012 pouch\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\n0\\n0\\n0\\n0","CERTUS PVP-1 PREP SWABSTICK  \\npovidone-iodine swab\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:75990-4019\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85H0HZU99M) \\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\nPOVIDONE-IODINE\\n0.1 mL  in 1 mL\\nInactive Ingredients\\nIngredient Name\\nStrength","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","GRX DYNE - povidone iodine solution \\n \\nGeritrex Corp.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nGRx Dyne Solution\\nDrug Facts\\nActive Ingredient:                      Purpose\\nPovidone Iodine USP, 10% w/v  Antiseptic\\n(equivalent to 1% titratable Iodine)\\nUses\\nFirst aid antiseptic to help the risk of infection in \\nminor cuts, scra...","Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\nkeep out of reach of children. If swallowed get medical help \\nor contact a Poison Control Center right away.\\nEnter section text here\\nGRX DYNE  \\npovidone iodine solution\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:54162-269\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85...","Geritrex Corp.\\nCITRIC ACID MONOHYDRATE\\n (UNII: 2968PHW8QP)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM HYDROXIDE\\n (UNII: 55X04QC32I)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:54162-269-16\\n472 mL in 1 BOTTLE, PLASTIC\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOTC monograph not final\\npart333A\\n05/16/2012\\nLabeler - \\n...","NUCYNTA - tapentadol hydrochloride tablet, film coated \\n \\nStat Rx USA\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use NUCYNTA\\u2122 safely and effectively. See full\\nprescribing information for NUCYNTA\\u2122.\\n \\nNUCYNTA\\u2122 (tapentadol) immediate-release oral tablets    C-II\\nInitial U.S. Approval: 2008\\nRECENT MAJOR CHANGES\\nWarnings and Precautions (\\n5.4\\n)\\nJune 2009\\nINDICATIONS AND USAGE\\nNUCYNTA\\u2122 is an opioid analgesic indicated for the relief o...","USE IN SPECIFIC POPULATIONS\\nLabor and delivery: \\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\nmothers have been taking NUCYNTA\\u2122, for respiratory depression. (\\n8.2\\n)\\nNursing mothers: should not breast-feed. (\\n8.3\\n)\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\n8.4\\n)\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\npatients with moder...","8.7 Hepatic Impairment\\n9 DRUG ABUSE AND DEPENDENCE\\n9.1 Controlled Substance\\n9.2 Abuse\\n9.3 Dependence\\n10 OVERDOSAGE\\n10.1 Human Experience\\n10.2 Management of Overdose\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n13 NON-CLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n13.2 Animal Toxicology and/or Pharmacology\\n14 CLINICAL STUDIES\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\n14.2 End-Stage Degenerative Joint Disea...","Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\nbeen studied and are not recommended.\\nNUCYNTA\\u2122 may be given with or without food \\n[see \\nClinical Pharmacology (12.3)\\n].\\n2.1 Renal Impairment\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\n[see \\nClinical\\nPharmacology (12.3)\\n]\\n.\\nNUCYNTA\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\nis not recommended.\\n2.2 Hepatic Im...","which may result in adverse cardiovascular events \\n[see \\nDrug Interactions (7.4)\\n]\\n.\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Respiratory Depression\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\nsignificantly decrease pulmonary ventilation.\\nNUCYNTA\\u2122 should be ...","5.5 Driving and Operating Machinery\\nPatients should be cautioned that NUCYNTA\\u2122 may impair the mental and/or physical abilities required\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\ncombination with alcohol or tranquilizers\\n [see \\nDrug Interactions (7.3)\\n]\\n.\\n5.6 Interactions with Alcohol and Drugs of Abuse\\nDue to its mu-opioid agonist activity,...","Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\nconsidered drug-related.\\nBased on data from nine Phase 2/3 studies that administered multiple...","*\\nInfections and infestations\\n  Nasopharyngitis\\n1\\n&lt;1\\n  Upper respiratory tract infection\\n1\\n&lt;1\\n  Urinary tract infection\\n1\\n&lt;1\\nMetabolism and nutrition disorders\\n  Decreased appetite\\n2\\n0\\nMusculoskeletal and connective tissue\\ndisorders\\n  Arthralgia\\n1\\n&lt;1\\nNervous system disorders\\n  Dizziness\\n24\\n8\\n  Somnolence\\n15\\n3\\n  Tremor\\n1\\n&lt;1\\n  Lethargy\\n1\\n&lt;1\\nPsychiatric disorders\\n  Insomnia\\n2\\n&lt;1\\n  Confusional state\\n1\\n0\\n  Abnormal dreams\\n1\\n&lt;1\\n  Anxiety\\n1\\n&lt;1\\nSkin and subcutaneous tissue disorders\\n  Pruritus\\n5\\n1\\n  Hyp...","Psychiatric disorders:\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\nabnormal\\nRenal and urinary disorders:\\n urinary hesitation, pollakiuria\\nRespiratory, thoracic and mediastinal disorders: \\noxygen saturation decreased, cough, dyspnea,\\nrespiratory depression\\nSkin and subcutaneous tissue disorders: \\nurticaria\\nVascular disorders:\\n blood pressure decreased\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\nNUCYNTA\\u2122,...","Pregnancy Category C.\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\nagonist properties.\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\nexhibit respiratory difficulties and withdrawal symptoms \\n[see \\nWarnings and Precautions (5.1)\\n]\\n. Use of\\nNUCYNTA\\u2122 in this population has not been characterized. As NUCYNTA\\u2122 h...","intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\nshould be taken to secure the airway.\\n11 DESCRIPTION\\nNUCYNTA\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\nThe chemical name is 3-[(1\\nR\\n,2\\nR\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\nmonohydrochloride. The structural formula is:\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\nH\\nNO\\u00b7HCl. The\\nn-octanol:water pa...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","Pharmacokinetic Drug Interactions\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\nconsidered clinically relevant and no change in dose is required.\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\nac...","14 CLINICAL STUDIES\\nThe efficacy and safety of NUCYNTA\\u2122 in the treatment of moderate to severe acute pain has been\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\u2122...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\nor greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus placebo.\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nNUCYNTA\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\nbiconvex-shaped.\\n50 mg tablets are yellow and debossed with \\"O-M\\" on one side and \\"50\\" on the other side, and are\\navailable in bottles of 100 (NDC 50458-820-04) a...","Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\u2122 \\n[see \\nUse in\\nSpecific Populations (8.3)\\n]\\n.\\n17.6 Monoamine Oxidase Inhibitors\\nPatients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine\\noxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\n17.7 Seizures\\nPatients should be informed that NU...","you get a new prescription. There may be new information. This Medication Guide does not take\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\ndoctor if you have any questions.\\nWhat is the most important information I should know about NUCYNTA\\u2122?\\nNUCYNTA\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\nUse NUCYNTA\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\u2122 if it has not been\\nprescribed for you.\\nYou sh...","Do not change the dose of NUCYNTA\\u2122 unless your doctor tells you to. \\nYour doctor may\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\u2122 more often\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\u2122.\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\u2122 to help lessen\\nwithdrawal symptoms.\\nNUCYNTA\\u2122 can be taken with or without food.\\nWhat should I avoid while taking NUCYNTA\\u2122?\\nDo not drive, operate machinery, ...","Store NUCYNTA\\u2122 at 59\\u00baF to 86\\u00baF (15\\u00baC to 30\\u00baC). Keep NUCYNTA\\u2122 tablets dry.\\nDispose of NUCYNTA\\u2122 tablets you no longer need.\\nKeep NUCYNTA\\u2122 in a safe place out of the reach of children.\\nGeneral information about NUCYNTA\\u2122\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\nuse NUCYNTA\\u2122 for a condition for which it was not prescribed. \\nDo not give NUCYNTA\\u2122 to other\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\u2122 could be harmful\\n...","NUCYNTA 100MG PACKAGE LABEL\\n       \\n   \\n   \\n   \\n   \\n   \\n   \\nNUCYNTA  \\ntapentadol hydrochloride tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN\\nPRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:16590-\\n863(NDC:50458-820)\\nRoute of Administration\\nORAL\\nDEA Schedule\\nCII","Active Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII: 15FIX9V2JP)\\n...","Stat Rx USA\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII:...","TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\n \\nAdvagen Pharma Limited\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use TIZANIDINE\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\n \\nInitial U.S. Approval: 1996\\nINDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...","Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\nfour-fold ( \\n8.5\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION.\\nRevised: 9/2020\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosing Information\\n2.2 Dosing in Patients with Renal Impairment\\n2.3 Dosing in Patients with Hepatic Impairment\\n2.4 Drug Discontinuation\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Hypo...","12.1 Mechanism of Action\\n12.3 Pharmacokinetics\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\n1 INDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\ntreatment with tizanid...","been studied.\\n2.2 Dosing in Patients with Renal Impairment\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\ndoses are required, individual doses rather than dosing frequency should be increased\\n[see Warnings and Precautions ( \\n5.7\\n)] \\n.\\n2.3 Dosing in Patients with Hepatic Impairment\\nT...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Clinical Pharmacology ( \\n12.3\\n)]\\n5.6 Hypersensitivity Reactions\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\nand symptoms occur. \\n[see Contraindications ( \\n4\\n)]\\n5.7 Increased Risk of Adverse Reactions in Patients...","264 patients received tizanidine and 261 patients received placebo. Across the three\\nstudies patient ages ranged from 15\\u201369 years and 51.4 percent were women. The\\nmedian dose during the plateau phase ranged from 20\\u201328 mg/day.\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\nclinical studies involving 264 patients with spasticity were dry mouth,\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\nThree-quarters of the patients rated t...","multiple sclerosis (Study 1) \\n[see Clinical Studies ( \\n14\\n)] \\n, the patients were specifically\\nasked if they had experienced any of the four most common adverse reactions: dry\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\nthese reactions is summarized in \\nTable 2\\n. Other events were, in general, reported at a\\nrate of 2% or less.\\nTable 2: Single Dose, Placebo-Controlled Study -...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","12.3\\n)]\\n7.7 \\u03b1 \\n-adrenergic agonists\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\nbe used with other \\u03b1 \\n-adrenergic agonists. \\n[see Warnings and Precautions ( \\n5.1\\n)]\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nPregnancy Category C\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...","8.6 Impaired Renal Function\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\nmore than 50%. In these patients, during titration, the individual doses should be\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\nshould be increased. These patients sho...","manifestations of tizanidine overdose were consistent with its known pharmacology. In\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\nmost often bradycardia and hypotension. Respiratory depression is another common\\nfeature of tizanidine overdose.\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\nmonitoring of cardiovascular and respiratory systems shou...","12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\nreduce facilitation of spinal motor neurons.\\n12.3 Pharmacokinetics\\nAbsorption and Distribution\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\n...","Metabolism and Excretion\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\u2013\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\nactive; their half-lives range from 20 to 40 hours.\\nFollowing single and multiple oral dosing of \\nC-tizanidine, an average of 60%...","this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\nused with caution in renally impaired patients \\n[see Warnings and Precautions ( \\n5.7\\n) and\\nUse in Specific Populations ( \\n8.6\\n)] \\n.\\nGender Effects\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\npharmacokinetic...","13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\nCarcinogenesis\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\nbasis.\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\nwhich is 2.5 times the MRHD on a mg/m \\nbasis. There was no increase in tumors in\\neither species.\\nMutagenesis\\nTizanidine was negative in \\nin vitro\\n(bacterial r...","tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\nincluding hypotension were more common and more severe than in the 8 mg group.\\nThere were no differences in the number of spasms occurring in each group.\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\nMeasured by ...","from baseline as measured by the Ashworth scale.\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\nAfter Dosing as Measured by the Ashworth Scale \\u00b1 95% Confidence Interval\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\nBaseline)\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...","17 PATIENT COUNSELING INFORMATION\\nSerious Drug Interactions\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\npharmacists when they start or stop taking any medication because of the risks\\nassociated with interaction between tizanidine and other medicines.\\nTizanidine Dosing\\nTell patients ...","PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15","TIZANIDINE HYDROCHLORIDE  \\ntizanidine hydrochloride capsule\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:72888-001\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of\\nStrength\\nStrength\\nTIZANIDINE HYDROCHLORIDE\\n (UNII: B53E3NMY5C) \\n(TIZANIDINE -\\nUNII:6AI06C00GW)\\nTIZANIDINE\\n2 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE...","AMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\nScore\\nno score\\nShape\\nCAPSULE\\nSize\\n11mm\\nFlavor\\nImprint Code\\nUpArrowhead;043\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:72888-001-\\n15\\n150 \\nin 1 BOTTLE; Type 0: Not a Combination\\nProduct\\n05/27/2020\\nMarketing Information\\nMarketing\\nCategory\\nAppl...","GELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPROPYL ALCOHOL\\n (UNII: ND2M416302)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nALCOHOL\\n (UNII: 3K9958V90M)\\n \\nBUTYL ALCOHOL\\n (UNII: 8PJ61P6TS3)\\n \\nAMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque)...","Inactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE, UNSPECIFIED\\n (UNII: 3NXW29V3WO)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nSTEARIC ACID\\n (UNII: 4ELV7Z65AP)\\n \\nGELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPRO...","Advagen Pharma Limited\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nRubicon Research\\nPrivate Limited\\n677604197\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\n \\nRevised: 7/2024","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\nhydrochlorothiazide tablet \\n \\nANI Pharmaceuticals, Inc.\\n----------\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\nWARNING: \\nFETAL TOXICITY\\n\\u2022\\n\\u2022\\nDESCRIPTION\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\nAT\\n) antagonist and a diuretic, hydrochlorothiazide.\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\np\\n-(\\no\\n-\\n1\\nH\\n...","Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\nand 12.5 mg or 25 mg of hydrochloroth...","The mechanism of the antihypertensive effect of thiazides is unknown.\\nPharmacokinetics\\nGeneral\\nCandesartan Cilexetil\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\nthe gastrointestinal tract to candesartan, a selective AT\\nsubtype angiotensin II receptor antagonist.\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\nIt undergoes minor hepatic\\nmetabolism by O-deethylation to an inactive metabolite. \\nThe elimination half...","Geriatric\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\u2265 65 years). \\nThe plasma\\nconcentration of candesartan was higher in the elderly (C\\n was approximately 50% higher, and AUC\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\nThe\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\nNo initia...","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","in myocardial infarction and cardiovascular mortality also have been seen regularly.\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\nhypertension can provide substantial benefit. \\nRelative risk reduction from blood pressure reduction is\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\nare at h...","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","considered if the intraocular pressure remains uncontrolled. \\nRisk factors for developing acute angle-\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\nHypersensitivity Reaction\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\nPRECAUTIONS\\nMetabolic Disturbances\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...","Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\npossible ac...","Cytotoxic products \\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\nCyclosporine \\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\ngout-type complications.\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\nhydrochlorothiazide. \\nThere was no evidence of c...","Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\nsubstituting for disordered renal function.\\nSafety and effectiveness in pediatric patients have not been established.\\nADVERSE REACTIONS\\nCandesartan Cilexetil and Hydrochlorothiazide\\nCandesartan cile...","melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\nfor white patients taking a cumulative dose of \\u226550,000 mg the risk increase was approximately 1\\nadditional SCC case for every 6,700 patients per year.\\nSkin:\\n \\nerythema multiforme including S...","Dose Titration by Clinical Effect: \\nA patient whose blood pressure is not controlled on 25 mg of\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\nA patient whose blood pressure is controlled on 25 mg of\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\nmg/12.5 mg and ser...","PRINCIPAL DISPLAY PANEL \\u2013 32 mg/12.5 mg\\nNDC 62559-661-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/12.5 mg\\nRx only\\n90 Tablets\\nPRINCIPAL DISPLAY PANEL \\u2013 32 mg/25 mg\\nNDC 62559-662-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/25 mg\\nRx only\\n90 Tablets","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:62559-660\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCANDESARTAN CILEXETIL\\n (UNII: R85M2X0D68) \\n(CANDESARTAN - UNII:S8Q36MD2XX)\\nCANDESARTAN\\nCILEXETIL\\n16 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n1...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","ANI Pharmaceuticals, Inc.\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-662-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nLabeler - \\nANI Pharmaceuticals, Inc. \\n(145588013)\\n \\nRevised: 5/2020","LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\ntablets tablet \\n \\nCipla USA Inc.\\n----------\\nLisinopril and Hydrochlorothiazide Tablets, USP\\nRx Only\\nWARNING: FETAL TOXICITY\\nSee full prescribing information for complete boxed warning.\\nWhen pregnancy is detected, discontinue lisinopril and\\nhydrochlorothiazide tablets as soon as possible.\\nDrugs that act directly on the renin-angiotensin system can cause\\ninjury and death to the developing fetus. See \\nWarnings: Fetal Toxicity\\n.\\n...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\nadministration of the separate entities.\\nLisinopril\\nMechanism of Action\\n \\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...","state is prolonged. Older patients, on average, have (approximately doubled) higher\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\npatients (see \\nDOSAGE AND ADMINISTRATION\\n). In a multiple dose pharmacokinetic study\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\nhe...","accompanied by some loss of potassium and bicarbonate.\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\nabout 6 to 12 hours.\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...","the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\nsimilar risk (See \\nWARNINGS\\n).\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\nthan in nonblack patients (see \\nWARNIN...","Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\ninhibitor may be at increased risk for angioedema (see \\nPRECAUTIONS\\n).\\nIntestinal Angioedema:\\n Intestinal angioedema has been reported in patients treated\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\nC-1...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\nLisinopril and Hydrochlorothiazide\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\nMaternal or fetotoxic effects were not seen in mice with the com...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","therapy.\\nInformation for Patients\\nAngioedema:\\n Angioedema, including laryngeal edema may occur at any time during\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\nconsulted with the prescribing physician.\\nSymp...","DOSAGE AND ADMINISTRATION\\n)\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\nInhibitors (COX-2 Inhibitors):\\n \\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\nfunction, including possible acute renal failure. These effects are usually reversible.\\nMonitor ...","mTOR (mammalian target of rapamycin) inhibitors\\n \\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\n(see \\nWARNINGS\\n)\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\nrisk for angioedema. (see \\nWARNINGS\\n)\\nHydrochlorothiazide\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\nAlcohol, barbiturates, or nar...","in vitro\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\nchromosomal aberrations in an \\nin vitro\\n test in Chinese hamster ovary cells or in an \\nin\\nvivo\\n study in mouse bone marrow.\\nLisinopril\\n \\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\nmaximum daily human dose, based on body weight and body surface area,\\nrespectively). There was no ...","Nursing Mothers\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\nrats contains radioactivity following administration of \\nC lisinopril. In another study,\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\nwhether to discontinue nursing and/or disco...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","In rare cases, intestinal angioedema has been reported in post marketing experience.\\nHypotension:\\n In clinical trials, adverse effects relating to hypotension occurred as\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\nWARNINGS\\n).\\nCough:\\n See \\nPRECAUTIONS - Cough\\n.\\nClinical Laboratory Test Findings Serum Electrolytes:\\n (See \\nPRECAUTIONS\\n).\\nCreatinine, Blood Urea Nitrogen:\\n Minor reversible incre...","hallucinations; \\nRespiratory:\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\nSkin:\\n Urticaria, alopecia,\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\npsoriasis, rare cases of other severe skin reactions, includin...","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","possible, be discontinued for two to three days before beginning therapy with lisinopril\\nto reduce the likelihood of hypotension (See \\nWARNINGS\\n). If the patient\\u2019s blood pressure\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\nfor at least an additional hour (See \\nWARNINGS\\n and \\nPRECAUTIONS\\n...","Protect from excessive light and humidity.\\n*AN69 is a registered trademark of Hospal Ltd.\\nManufactured by:\\nInvaGen Pharmaceuticals, Inc.\\n(a subsidiary of Cipla Ltd.)\\nHauppauge, NY 11788\\nManufactured for:\\nCipla USA, Inc.\\n10 Independence Boulevard, Suite 300\\nWarren, NJ 07059\\nRevised: 10/2021\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\u2013 10 mg/12.5 mg\\nNDC 69097-968-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n10 mg/12.5 mg\\n100 Tablets\\nCipla\\nNDC 69097-969-07             ...","Cipla\\nNDC 69097-971-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n20 mg/25 mg\\n100 Tablets\\nCipla\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","lisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-969\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS D...","LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-971\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n25 mg\\nInactive Ingredients\\nI...","Cipla USA Inc.\\nLabeler - \\nCipla USA Inc. \\n(078719707)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen\\nPharmaceuticals, Inc\\n165104469\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\n69097-969, 69097-971)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen Pharmaceuticals, Inc\\n080334903\\npack(69097-968, 69097-969, 69097-971)\\n \\nRevised: 11/2021"]],["color",{"type":"ndarray","array":["#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4"],"shape":[117],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1287","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1288"}}},"glyph":{"type":"object","name":"Scatter","id":"p1283","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1284","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1285","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1254","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1269","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1270"},{"type":"object","name":"WheelZoomTool","id":"p1271","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1272","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1273","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1278"},{"type":"object","name":"SaveTool","id":"p1279"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1264","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1265","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1266"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1267"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1259","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1260","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1261"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1262"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1263","attributes":{"axis":{"id":"p1259"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1268","attributes":{"dimension":1,"axis":{"id":"p1264"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1289","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1290","attributes":{"label":{"type":"value","value":"Prescription Drugs"},"renderers":[{"id":"p1286"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1291","attributes":{"label":{"type":"value","value":"Tizanidine Pharmacology"},"renderers":[{"id":"p1286"}],"index":47}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1361","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1297","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1306","attributes":{"start":-11.49420461654663,"end":-3.3945081710815432}},"y_range":{"type":"object","name":"Range1d","id":"p1307","attributes":{"start":-2.7184320986270905,"end":10.954908847808838}},"x_scale":{"type":"object","name":"LinearScale","id":"p1308"},"y_scale":{"type":"object","name":"LinearScale","id":"p1309"},"title":{"type":"object","name":"Title","id":"p1304","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1336","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1293","attributes":{"selected":{"type":"object","name":"Selection","id":"p1294","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1295"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"GwMhwTQ2/MDP5AHB7ycLwWh678CYvyzBGiAewWw2EsFe5y/BVE0bwRO7JcE37yfBHBopwbbzHsGl2BnBrlgSwaYFKcF10/TA2rcXwTlFBsEN9/fAiqcmwQEaAcHCTh/B7q0gwQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"7YSEQE2z00BJgIw/EhYFQVNC+0Av3kY/pQvhvtTuP76/d4VAcKqbQGC92ED6XqpAeVq8PrN7pD+pY7Y/0Ha2QBXl/0AYa4Q/r3CYQIR83kChGdQ/0NqOQPnQCkFMI4Q9vpmJQA=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["Antihypertensive Medications","Lisinopril and Hydrochlorothiazide","Tapentadol Medication","Lisinopril and Hydrochlorothiazide","Lisinopril and Hydrochlorothiazide","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Antihypertensive Medications","Antihypertensive Medications","Antihypertensive Medications","Antihypertensive Medications","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Tizanidine Hydrochloride","Lisinopril and Hydrochlorothiazide","Antihypertensive Medications","Tapentadol Medication","Antihypertensive Medications","Lisinopril and Hydrochlorothiazide","Tapentadol Medication","Antihypertensive Medications","Lisinopril and Hydrochlorothiazide","Tizanidine Hydrochloride","Antihypertensive Medications"]],["correctness",[true,true,true,true,true,true,true,true,true,true,true,false,true,true,true,true,false,true,true,false,true,false,false,false,false]],["questions",["What are the specific active ingredients present in the product manufactured by C&amp;BCOSMETIC Co.,Ltd. and their respective quantities per 100 mL?","How is lisinopril primarily eliminated from the body and under what condition does the decrease in its elimination become clinically significant?","What were the most common systemic effects observed in toxicological studies with tapentadol, and what specific properties of the compound were they related to?","What are the clinical signs and symptoms of fluid and electrolyte imbalance that patients undergoing thiazide therapy should be monitored for, and what are some specific conditions that may exacerbate these imbalances?","What are the specific contraindications for the usage of lisinopril and hydrochlorothiazide tablets, and in which patient populations should caution be exercised when prescribing this medication?","What are the differences in bioavailability between Tizanidine Capsules and Tizanidine Tablets when administered with food?","What are the potential adverse reactions that may occur when tizanidine is taken with CYP1A2 inhibitors, and what precautions should be taken to minimize the risk of these reactions?","What are the specific effects that result from the combined use of tizanidine and fluvoxamine, leading to the contraindication of their concomitant administration?","When did the marketing of the product with NDC:75990-4019-4 commence according to the provided document?","When did the marketing of the product associated with application number ANDA205181 by Rite Aid Corporation commence?","What are the specific medical conditions or situations that warrant the use of candesartan cilexetil and hydrochlorothiazide tablets according to the indications and usage provided?","What are the active ingredients and their respective strengths in the tablet with Item Code NDC:62559-660-90?","In multiple dose, placebo-controlled clinical studies involving patients with spasticity who received tizanidine, what were the most common adverse reactions reported and how were these events rated by the patients?","What are the common symptoms associated with an overdose of tizanidine, including changes in consciousness, cardiac function, and respiratory function?","What is the recommended initial starting dose for Tizanidine hydrochloride capsules, and how often can this dose be repeated within a 24-hour period?","What is the potency of Lisinopril and Hydrochlorothiazide tablets in terms of milligrams for each component?","What are some of the adverse reactions that have been reported in adults taking candesartan cilexetil and hydrochlorothiazide tablets, and what conditions should be monitored before initiating therapy with these tablets?","In humans, what are the main pathways through which tapentadol is metabolized, and what percentage of the dose is excreted in urine in the conjugated form after oral administration?","What is the National Drug Code (NDC) number specifically assigned to the 6 mg 150 Capsules Bottle?","What is the recommended dosage range for lisinopril monotherapy in the treatment of hypertension, and what factors should be considered when determining the appropriate dosage for a patient switching from monotherapy to combination therapy?","What was the dosing schedule and dosage of NUCYNTA\\u2122 administered in the study focusing on end-stage degenerative joint disease, and what were the conditions for patients to be included in the study?","Could you describe the color, shape, and size of the product mentioned in the document, and what is the flavor and imprint code associated with it?","What specific precautions should be taken into account when administering lisinopril to patients with impaired renal function, considering the potential changes in renal function and the risk of oliguria, progressive azotemia, acute renal failure, and death associated with angiotensin-converting enzyme inhibitors?","What are the specific withdrawal adverse reactions associated with tizanidine, and what precautions should be taken to minimize the risk of these reactions, especially for patients on high doses for an extended period or concurrently using narcotics?","What are the active ingredients and their respective strengths found in the tizanidine hydrochloride capsules?"]],["agent_answer",["Based on the provided context, the active ingredients in the product manufactured by C&amp;BCOSMETIC Co.,Ltd. and their quantities per 100 mL are:  \\n\\n- **NIACINAMIDE**: 2 g in 100 mL (UNII: 25X51I8RD4)  \\n- **TITANIUM DIOXIDE**: 4.694 g in 100 mL (UNII: 15FIX9V2JP)  \\n- **ADENOSINE**: 0.04 g in 100 mL (UNII: K72T3FS567)  \\n- **OCTINOXATE**: 7 g in 100 mL (UNII: 4Y5P7MUD51)  \\n\\nThese are the confirmed active ingredients with their respective strengths as listed in the document.","Based on the context provided:\\n\\nLisinopril is primarily eliminated unchanged entirely through the kidneys (excreted in the urine). It does not undergo metabolism. \\n\\nThe decrease in elimination of lisinopril becomes clinically important only when the glomerular filtration rate (a measure of kidney function) falls below 30 mL/min. Above this threshold, the elimination half-life remains largely unchanged. When renal function is more severely impaired (below 30 mL/min), peak and trough lisinopril levels increase, time to peak concentration increases, and time to attain steady state is prolonged.","The most common systemic effects observed in toxicological studies with tapentadol were related to its **mu-opioid receptor agonist** and **norepinephrine reuptake inhibition** pharmacodynamic properties. These effects included transient, dose-dependent, and predominantly CNS-related findings such as impaired respiratory function and convulsions. The convulsions were observed in dogs at plasma levels (Cmax) within the range associated with the maximum recommended human dose (MRHD).  \\n\\n*(Source: Document metadata for NUCYNTA\\u2122 (tapentadol), page 15)*  \\n\\nLet me know if you&#x27;d like further details!","Based on the provided context, here are the clinical signs and symptoms of fluid and electrolyte imbalance in patients receiving thiazide therapy and conditions that may exacerbate them:\\n\\n**Clinical signs/symptoms to monitor:**  \\n- Dryness of mouth  \\n- Thirst  \\n- Weakness  \\n- Lethargy  \\n- Drowsiness  \\n- Restlessness  \\n- Confusion  \\n- Seizures  \\n- Muscle pains or cramps  \\n- Muscular fatigue  \\n- Hypotension  \\n- Oliguria (reduced urine output)  \\n- Tachycardia (rapid heart rate)  \\n- Gastrointestinal disturbances (e.g., nausea, vomiting)  \\n\\n**Specific conditions exacerbating imbalances:**  \\n- **Brisk diuresis** (increases risk of hypokalemia).  \\n- **Severe cirrhosis** (elevates hypokalemia risk).  \\n- **Prolonged therapy** (heightens electrolyte imbalances).  \\n- **Inadequate oral electrolyte intake** (worsens hypokalemia).  \\n- **Excessive vomiting or parenteral fluid administration** (requires close serum/urine electrolyte monitoring).  \\n- **Hot weather in edematous patients** (may cause dilutional hyponatremia).  \\n\\nThiazides can also lead to **hypomagnesemia**, **hypercalcemia**, **hyperuricemia/gout**, and **hyperglycemia** (particularly unmasking latent diabetes). \\n\\n(Source: Context snippets from *Lisinopril and Hydrochlorothiazide Tablets, USPRx Only* documents.)","Based on the provided context, here are the specific contraindications and patient populations requiring caution for lisinopril and hydrochlorothiazide tablets:  \\n\\n### **Contraindications:**  \\n1. **Hypersensitivity** to the product or any of its components.  \\n2. **History of angioedema** related to previous treatment with an ACE inhibitor.  \\n3. Patients with **hereditary or idiopathic angioedema**.  \\n4. **Anuria** (due to the hydrochlorothiazide component).  \\n5. **Hypersensitivity to sulfonamide-derived drugs** (also due to hydrochlorothiazide).  \\n6. **Combination with neprilysin inhibitors** (e.g., sacubitril).  \\n\\n### **Populations Requiring Caution:**  \\n- **Black patients**: Higher risk of ACE inhibitor-associated angioedema compared to nonblack patients.  \\n- **Patients with renal impairment or collagen vascular disease**: Due to risk of agranulocytosis (observed with captopril; insufficient data to rule out similar risk with lisinopril).  \\n- **Elderly patients**: Increased likelihood of impaired renal, hepatic, or cardiac function. Dose adjustments may be necessary.  \\n\\nThe document does not provide additional contraindications or cautions beyond these. Let me know if you&#x27;d like further details from the context.","Based on the provided context, here are the differences in bioavailability between Tizanidine Capsules and Tizanidine Tablets when administered with food:  \\n\\n1. **Mean Maximal Plasma Concentration (Cmax):**  \\n   - Tablets: Increased by ~30% when administered with food.  \\n   - Capsules: Decreased by ~20% when administered with food.  \\n   - Consequently, the mean Cmax for capsules is ~66% that of tablets when both are taken with food.  \\n\\n2. **Time to Peak Plasma Concentration (Tmax):**  \\n   - Tablets: Increased by 25 minutes (to 1 hour and 25 minutes) with food.  \\n   - Capsules: Increased by 2 to 3 hours with food.  \\n\\n3. **Extent of Absorption:**  \\n   - Tablets: Increased by ~30% with food.  \\n   - Capsules: Increased by ~10% with food.  \\n   - As a result, the amount absorbed from capsules is about 80% of that from tablets when both are taken with food.  \\n\\n4. **Bioequivalence:**  \\n   - Under fasting conditions, tizanidine capsules and tablets are bioequivalent.  \\n   - Under fed conditions, they are **not bioequivalent**.  \\n\\nThese differences mean that switching between formulations or administration conditions (fed vs. fasted) could lead to changes in efficacy or adverse effects.","Based on the context provided, the potential adverse reactions when tizanidine is taken with CYP1A2 inhibitors include:  \\n- **Hypotension** (low blood pressure)  \\n- **Bradycardia** (slow heart rate)  \\n- **Excessive drowsiness**  \\n\\n### Precautions to Minimize Risk:  \\n1. **Avoid concomitant use** unless clinically necessary.  \\n2. If use is unavoidable:  \\n   - **Initiate tizanidine at a low dose (2 mg)**.  \\n   - Increase cautiously in **2\\u20134 mg steps daily** based on patient response.  \\n3. **Monitor closely** for adverse reactions. If they occur:  \\n   - **Reduce the dose** or **discontinue tizanidine**.  \\n4. Use extra caution with **renal impairment** (creatinine clearance &lt; 25 mL/min).  \\n\\n*Notable CYP1A2 inhibitors mentioned include zileuton, fluoroquinolones (excluding ciprofloxacin, which is contraindicated), antiarrhythmics (amiodarone, mexiletine, propafenone, verapamil), cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine.*  \\n\\nWould you like additional details from the context?","The specific effects resulting from the combined use of tizanidine and fluvoxamine, leading to their contraindication, are:\\n\\n1. **Significantly decreased blood pressure**  \\n2. **Increased drowsiness**  \\n3. **Increased psychomotor impairment**  \\n\\nThese effects occur due to changes in the pharmacokinetics of tizanidine when administered with fluvoxamine. The combination is contraindicated because of these severe adverse reactions.  \\n\\nSource: *Tizanidine Hydrochloride Capsules prescribing information, Drug Interactions section (7.1)*.","I don&#x27;t know. The provided context does not contain information about a product with NDC:75990-4019-4.","The marketing of the product associated with application number ANDA205181 by Rite Aid Corporation commenced on **11/17/2017**.  \\n\\nSource:  \\n```\\nMarketing Start Date: 11/17/2017  \\nApplication Number: ANDA205181  \\nLabeler: Rite Aid Corporation  \\n```","Candesartan cilexetil and hydrochlorothiazide tablets are specifically indicated for the **treatment of hypertension (high blood pressure)** to lower blood pressure. The context states that lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. \\n\\nNo other specific medical conditions or situations are mentioned in the provided context as indications for this drug combination. It is explicitly noted that **there are no controlled trials demonstrating risk reduction** with candesartan cilexetil and hydrochlorothiazide tablets beyond hypertension management. \\n\\nThe context also emphasizes that control of high blood pressure should be part of **comprehensive cardiovascular risk management**, including lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake, but these are adjunct measures, not additional indications for the drug itself.","Based on the provided context, I don&#x27;t have the information about the active ingredients and their strengths for the tablet with Item Code NDC:62559-660-90. The documents don&#x27;t contain this specific detail. I cannot provide an answer to this question.","Based on the context provided, in multiple dose, placebo-controlled clinical studies involving 264 patients with spasticity who received tizanidine, the most frequent adverse reactions reported were:  \\n\\n1. **Dry mouth** (49% in tizanidine group vs. 10% placebo)  \\n2. **Somnolence/sedation** (48% vs. 10%)  \\n3. **Asthenia (weakness, fatigue, and/or tiredness)** (41% vs. 16%)  \\n4. **Dizziness** (16% vs. 4%)  \\n\\n**Patient-rated severity**:  \\n- Three-quarters (75%) of the patients rated these events as **mild to moderate**.  \\n- One-quarter (25%) rated them as **severe**.  \\n- These events appeared to be **dose-related**.  \\n\\n(Source: Table 1 from the provided clinical study data on tizanidine.)","Based on the provided context, the common symptoms associated with a tizanidine overdose include:  \\n\\n- **Changes in consciousness:** Lethargy, somnolence, confusion, and coma.  \\n- **Cardiac dysfunction:** Bradycardia (slow heart rate) and hypotension (low blood pressure).  \\n- **Respiratory dysfunction:** Respiratory depression (slowed or difficulty breathing).  \\n\\nAdditionally, the document states that symptoms generally resolve within **one to three days** after discontinuing tizanidine and providing appropriate medical care. Dialysis is **not effective** for removing tizanidine from the body due to its lipid solubility and low water solubility.","The recommended starting dose for Tizanidine hydrochloride capsules is 2 mg. This dose can be repeated at 6 to 8-hour intervals, as needed, up to a maximum of three doses in 24 hours.","Based on the provided context, Lisinopril and Hydrochlorothiazide tablets are available in the following potency combinations:  \\n- **10 mg/12.5 mg** (Lisinopril/Hydrochlorothiazide)  \\n- **20 mg/12.5 mg**  \\n- **20 mg/25 mg**.  \\n\\nNo other details or interpretations are included beyond this information. Let me know if you need further clarification!","From the provided context, here are the adverse reactions reported for candesartan cilexetil and hydrochlorothiazide tablets in adults:  \\n\\n**Adverse Reactions:**  \\n1. **Respiratory System Disorder:** Upper respiratory tract infection (3.6% vs 3.0% placebo).  \\n2. **Body as a Whole:** Back pain (3.3% vs 2.4% placebo); influenza-like symptoms (2.5% vs 1.9% placebo).  \\n3. **Central/Peripheral Nervous System:** Dizziness (2.9% vs 1.2% placebo).  \\n\\nAdditionally, very rare post-marketing reports include:  \\n- **Digestive:** Abnormal hepatic function and hepatitis.  \\n- **Hematologic:** Neutropenia, leukopenia, agranulocytosis.  \\n- **Immunologic:** Angioedema.  \\n- **Metabolic:** Hyperkalemia, hyponatremia.  \\n- **Respiratory:** Cough.  \\n- **Skin disorders:** Pruritus, rash, urticaria.  \\n\\n**Conditions to Monitor Before Initiating Therapy:**  \\n- **Volume/salt depletion** should be corrected due to the risk of symptomatic hypotension.  \\n- **Renal function and blood pressure** should be closely monitored, especially in patients with:  \\n  - Heart failure (risk of oliguria, azotemia, or acute renal failure).  \\n  - Impaired renal function (risk of acute renal failure).  \\n\\nWould you like any additional details from the documents?","In humans, tapentadol is mainly metabolized via **Phase 2 pathways** (primarily conjugation with glucuronic acid to produce glucuronides). Only a small amount is metabolized by **Phase 1 oxidative pathways**.  \\n\\nAfter oral administration, approximately **70% of the dose** is excreted in urine in the conjugated form (comprising **55% O-glucuronide and 15% sulfate** of tapentadol). A total of **3% of the drug** is excreted unchanged in urine.  \\n\\nThe metabolites (such as N-desmethyl tapentadol and hydroxy tapentadol) do not contribute to the analgesic activity.  \\n*Source: NUCYNTA\\u2122 prescribing information (page 14).*","The NDC number for the 6 mg capsules (150 capsules bottle) is **NDC 72888-003-15**. \\n\\n(Source: Context mentions \\"The 6 mg capsules have Size 2 Hard gelatin capsule... bottles of 150 capsules (NDC 72888-003-15)\\").","Based on the provided context, the recommended dosage range for lisinopril monotherapy in the treatment of hypertension is **10 mg to 80 mg per day** (as observed in clinical trials for combination therapy). \\n\\nWhen switching from monotherapy to combination therapy (lisinopril/hydrochlorothiazide), the following factors should be considered:  \\n1. **Clinical Response**: Blood pressure should be measured at the interdosing interval to ensure adequate antihypertensive effect.  \\n2. **Dose Titration**: The hydrochlorothiazide dose should generally not be increased until **2 to 3 weeks** have elapsed. After adding the diuretic, it may be possible to reduce the lisinopril dose.  \\n3. **Potassium Levels**: Patients experiencing significant potassium loss on hydrochlorothiazide monotherapy may benefit from switching to a combination (e.g., **10 mg/12.5 mg lisinopril/hydrochlorothiazide**) to improve blood-pressure control without electrolyte disturbance.  \\n4. **Dose-Dependent Side Effects**: Combination therapy should ideally be initiated only after monotherapy fails to achieve the desired effect, to minimize side effects like hypokalemia.  \\n\\nThe initial switch could involve doses like **10 mg/12.5 mg or 20 mg/12.5 mg lisinopril/hydrochlorothiazide**, depending on the current monotherapy dose. Further adjustments should be guided by clinical response.  \\n\\n(No other details outside the context were included.)","Based on the context provided:\\n\\nDosing schedule and dosage:\\n- NUCYNTA\\u2122 was administered at doses of 50 mg and 75 mg.\\n- The medication was given every 4 to 6 hours during waking hours for 10 days.\\n- For the 75 mg treatment group: patients received 50 mg on the first day of the study, followed by 75 mg for the remaining nine days.\\n\\nPatient inclusion conditions:\\n- Patients aged 18 to 80 years experiencing moderate to severe pain from end-stage degenerative joint disease of the hip or knee.\\n- Defined as having a 3-day mean pain score of \\u22655 on an 11-point pain intensity scale (ranging from 0 to 10).\\n- Patients were allowed to continue non-opioid analgesic therapy if they had been on a stable regimen before screening.\\n- Patients requiring rescue analgesics other than study medication were discontinued for lack of efficacy.","Based on the context provided, I do not have information about a product&#x27;s color, shape, size, flavor, or imprint code in a single document that includes all these details. The context contains fragmented or incomplete information, so I cannot provide a complete description.  \\n\\nFor example:  \\n- **Albertsons Signature Care Pain Relief Patch** mentions `Shape: RECTANGLE` but does not specify color, flavor, or imprint code.  \\n- **Ivermectin** mentions `Color: WHITE (off-white/tan)` but lacks other characteristics.  \\n\\nSince the context does not contain a single product with all the requested details, I cannot provide a complete answer. Would you like me to extract any specific partial details?","From the provided context, the following precautions should be taken when administering lisinopril to patients with impaired renal function:\\n\\n1. **Close Medical Supervision**: Therapy should be started under very close medical supervision due to the potential fall in blood pressure, which could lead to oliguria, progressive azotemia, and rarely acute renal failure or death (Document with page_label &#x27;7&#x27;).\\n\\n2. **Monitoring and Follow-up**: Patients should be followed closely for the first two weeks of treatment and whenever the dose of lisinopril and/or diuretic is increased (Document with page_label &#x27;7&#x27;).\\n\\n3. **Risk in Certain Patient Groups**: Similar precautions apply to patients with ischemic heart or cerebrovascular disease, as an excessive fall in blood pressure could result in adverse outcomes (Document with page_label &#x27;7&#x27;).\\n\\n4. **Renal Function Monitoring**: In hypertensive patients with no apparent pre-existing renal vascular disease, minor and transient increases in blood urea and serum creatinine may occur, especially when lisinopril is given concomitantly with a diuretic. This is more likely in patients with pre-existing renal impairment. Dosage reduction of lisinopril and/or discontinuation of the diuretic may be required (Document with page_label &#x27;10&#x27;).\\n\\n5. **Evaluation of Renal Function**: Evaluation of the hypertensive patient should always include assessment of renal function (Document with page_label &#x27;10&#x27;).\\n\\n6. **Hyperkalemia Risk**: Hyperkalemia (serum potassium &gt;5.7 mEq/L) occurred in approximately 1.4% of hypertensive patients treated with lisinopril plus hydrochlorothiazide. Risk factors include renal insufficiency, diabetes, and concomitant use of potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes (Document with page_label &#x27;10&#x27;).\\n\\nThese precautions emphasize the need for careful monitoring, dose adjustments, and close supervision to mitigate risks in patients with impaired renal function.","Based on the provided context, here are the specific withdrawal adverse reactions associated with tizanidine and the precautions to minimize their risk:  \\n\\n### **Withdrawal Adverse Reactions:**  \\n1. **Hypertension**  \\n2. **Tachycardia**  \\n3. **Hypertonia**  \\n4. **Tremor**  \\n5. **Anxiety**  \\n\\n### **Precautions to Minimize Risk:**  \\n- Discontinue tizanidine **slowly** (dosage should be tapered gradually).  \\n- Exercise increased caution in patients on **high doses** for **prolonged periods**.  \\n- Be especially vigilant when tizanidine is used **concomitantly with narcotics**, as withdrawal symptoms may be more severe.  \\n\\nThese recommendations are supported by case reports and observations from safety surveillance data. No reversal of withdrawal signs was observed with naloxone, suggesting alternative management strategies are needed.  \\n\\n(Source: Tizanidine Hydrochloride Capsules prescribing information, pages 10-11.)  \\n\\nLet me know if you need any additional details!","Based on the provided context, the active ingredient and its strength in tizanidine hydrochloride capsules are:\\n\\n**Active Ingredient:**  \\n- TIZANIDINE HYDROCHLORIDE (UNII: B53E3NMY5C) / TIZANIDINE (UNII: 6AI06C00GW)  \\n\\n**Strength:**  \\n- TIZANIDINE 4 mg (per capsule).  \\n\\nThe context also mentions that the capsules contain tizanidine hydrochloride equivalent to 4 mg tizanidine base.  \\n\\n(Note: The context provided repeats the same information for the 4 mg capsules. If there were other strengths like 2 mg or 6 mg mentioned in other parts of the document, they are not included in the provided excerpts.)"]],["reference_answer",["The active ingredients in the product from C&amp;BCOSMETIC Co.,Ltd. are Niacinamide, Titanium Dioxide, Adenosine, and Octinoxate.","Lisinopril is excreted unchanged entirely in the urine. It does not undergo metabolism.","In toxicological studies with tapentadol, the most common systemic effects were related to the mu-opioid receptor agonist and norepinephrine reuptake inhibition properties of the compound. Transient, dose-dependent, and predominantly CNS-related findings were observed, including impaired respiratory function and convulsions.","Patients receiving thiazide therapy should be observed for warning signs or symptoms of fluid and electrolyte imbalance, such as dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances like nausea and vomiting.","Lisinopril and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to this product, in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor, in patients with hereditary or idiopathic angioedema, in patients with anuria or hypersensitivity to other sulfonamide-derived drugs, and in combination with a neprilysin inhibitor (e.g., sacubitril).","Tizanidine capsules and tizanidine tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. The mean Cmax for the capsule when administered with food is approximately 66% the Cmax for the tablet when administered with food.","Adverse reactions such as hypotension, bradycardia, or excessive drowsiness can occur when tizanidine is taken with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than ciprofloxacin, antiarrhythmics, cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine.","Concomitant use of fluvoxamine and tizanidine is contraindicated due to changes in the pharmacokinetics of tizanidine when administered with fluvoxamine, which resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.","The marketing start date for the product with NDC:75990-4019-4 is 05/01/2011.","The marketing start date for the product with application number ANDA205181 by Rite Aid Corporation is 11/17/2017.","Candesartan cilexetil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.","The active ingredients in the tablet with Item Code NDC:62559-660-90 are Candesartan Cilexetil (16 mg) and Hydrochlorothiazide (12.5 mg).","The most frequent adverse reactions reported in multiple dose, placebo-controlled clinical studies involving 264 patients with spasticity who received tizanidine were dry mouth, somnolence/sedation, asthenia (weakness, fatigue and/or tiredness), and dizziness.","Manifestations of tizanidine overdose include a decrease in sensorium with symptoms such as lethargy, somnolence, confusion, and coma. Depressed cardiac function is observed with bradycardia and hypotension, as well as respiratory depression. Basic steps to ensure airway adequacy and monitoring of cardiovascular and respiratory systems should be taken in case of overdose.","The recommended starting dose for Tizanidine hydrochloride capsules is 2 mg. This dose can be repeated at 6 to 8 hour intervals, up to a maximum of 3 doses in 24 hours.","The strength of Lisinopril and Hydrochlorothiazide tablets is 20 mg/25 mg.","Adverse reactions reported in adults taking candesartan cilexetil and hydrochlorothiazide tablets include symptomatic hypotension, fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions.","Tapentadol is mainly metabolized via Phase 2 pathways, particularly through conjugation with glucuronic acid to produce glucuronides. Only a small amount of tapentadol is metabolized by Phase 1 oxidative pathways.","The NDC number for the 6 mg 150 Capsules Bottle is 72888-003-15.","Lisinopril monotherapy is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg.","In the study for end-stage degenerative joint disease, patients were given 50 mg of NUCYNTA\\u2122 for the first day, followed by 75 mg for the remaining nine days. The medication was administered every 4 to 6 hours during waking hours for a total of 10 days.","The product is white (Off-White) in color, oval in shape, and has a size of 17mm.","When administering lisinopril to patients with impaired renal function, changes in renal function may be anticipated. In patients with severe congestive heart failure, treatment with lisinopril may be associated with oliguria, progressive azotemia, acute renal failure, and even death. Increases in blood urea nitrogen and serum creatinine may occur in hypertensive patients with unilateral or bilateral renal artery stenosis. Renal function should be monitored during the first few weeks of therapy, and dosage reduction or discontinuation of the diuretic may be required in some cases.","Withdrawal adverse reactions associated with tizanidine include rebound hypertension, tachycardia, and hypertonia. It is recommended to decrease the dose slowly to minimize the risk of these reactions.","The active ingredient in the tizanidine hydrochloride capsules is Tizanidine Hydrochloride, with a strength of 4 mg in one capsule and 6 mg in another capsule."]],["id",[12,94,38,102,97,61,53,57,20,9,78,90,55,60,49,114,80,37,68,111,40,4,101,54,70]],["content",["C&amp;BCOSMETIC Co.,Ltd.\\nNIACINAMIDE\\n (UNII: 25X51I8RD4) \\n(NIACINAMIDE - UNII:25X51I8RD4)\\nNIACINAMIDE\\n2 g  in 100 mL\\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP) \\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\nTITANIUM DIOXIDE\\n4.694 g  in 100 mL\\nADENOSINE\\n (UNII: K72T3FS567) \\n(ADENOSINE - UNII:K72T3FS567)\\nADENOSINE\\n0.04 g  in 100 mL\\nOCTINOXATE\\n (UNII: 4Y5P7MUD51) \\n(OCTINOXATE - UNII:4Y5P7MUD51)\\nOCTINOXATE\\n7 g  in 100 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C...","Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\nadministration of the separate entities.\\nLisinopril\\nMechanism of Action\\n \\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...","Pharmacokinetic Drug Interactions\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\nconsidered clinically relevant and no change in dose is required.\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\nac...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\nsimilar risk (See \\nWARNINGS\\n).\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\nthan in nonblack patients (see \\nWARNIN...","12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\nreduce facilitation of spinal motor neurons.\\n12.3 Pharmacokinetics\\nAbsorption and Distribution\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\n...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","Rite Aid Corporation\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nANDA\\nANDA205181\\n11/17/2017\\nLabeler - \\nRite Aid Corporation \\n(014578892)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nTaro Pharmaceuticals Inc.\\n206263295\\nmanufacture(11822-2100)\\n \\nRevised: 7/2024","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","264 patients received tizanidine and 261 patients received placebo. Across the three\\nstudies patient ages ranged from 15\\u201369 years and 51.4 percent were women. The\\nmedian dose during the plateau phase ranged from 20\\u201328 mg/day.\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\nclinical studies involving 264 patients with spasticity were dry mouth,\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\nThree-quarters of the patients rated t...","manifestations of tizanidine overdose were consistent with its known pharmacology. In\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\nmost often bradycardia and hypotension. Respiratory depression is another common\\nfeature of tizanidine overdose.\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\nmonitoring of cardiovascular and respiratory systems shou...","TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\n \\nAdvagen Pharma Limited\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use TIZANIDINE\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\n \\nInitial U.S. Approval: 1996\\nINDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...","Cipla\\nNDC 69097-971-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n20 mg/25 mg\\n100 Tablets\\nCipla\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","Clinical Pharmacology ( \\n12.3\\n)]\\n5.6 Hypersensitivity Reactions\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\nand symptoms occur. \\n[see Contraindications ( \\n4\\n)]\\n5.7 Increased Risk of Adverse Reactions in Patients...","AMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\nScore\\nno score\\nShape\\nCAPSULE\\nSize\\n11mm\\nFlavor\\nImprint Code\\nUpArrowhead;043\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:72888-001-\\n15\\n150 \\nin 1 BOTTLE; Type 0: Not a Combination\\nProduct\\n05/27/2020\\nMarketing Information\\nMarketing\\nCategory\\nAppl..."]],["color",["#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#0a980a","#ba0e0e","#0a980a","#0a980a","#0a980a","#0a980a","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1337","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1338"}}},"glyph":{"type":"object","name":"Scatter","id":"p1333","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1334","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1335","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1351","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1342","attributes":{"selected":{"type":"object","name":"Selection","id":"p1343","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1344"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1352","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1353"}}},"glyph":{"type":"object","name":"Scatter","id":"p1348","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1349","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1350","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1305","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1320"},{"type":"object","name":"WheelZoomTool","id":"p1321","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1322","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1323","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1328"},{"type":"object","name":"SaveTool","id":"p1329"},{"type":"object","name":"HoverTool","id":"p1296","attributes":{"renderers":[{"id":"p1336"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1315","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1316","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1317"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1318"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1310","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1311","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1312"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1313"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1314","attributes":{"axis":{"id":"p1310"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1319","attributes":{"dimension":1,"axis":{"id":"p1315"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1339","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1340","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p1336"}],"index":11}},{"type":"object","name":"LegendItem","id":"p1341","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1336"}],"index":0}}]}},{"type":"object","name":"LabelSet","id":"p1357","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1354","attributes":{"selected":{"type":"object","name":"Selection","id":"p1355","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1356"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"akEQwdI6IME="},"shape":[2],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"lImZQKqW2z4="},"shape":[2],"dtype":"float32","order":"little"}],["topic",["Prescription Drugs","Tizanidine Pharmacology"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"0ae75cde-86b6-472e-900c-46586da3b0a8","roots":{"p1362":"a5e774ac-96ea-4b68-bf2d-9281de0d0c2a"},"root_ids":["p1362"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="a5e774ac-96ea-4b68-bf2d-9281de0d0c2a" data-root-id="p1362" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
